España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Principal Investment Grade Corporate Active ETF
IG
ARCA
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$20.70
0.02
0.09%
At close: -
Get Report
Comment
Overview
News
Holdings
Dividends
Short Interest
Latest news for Principal Investment Grade Corporate Active ETF (ARCA:IG)
Principal Investment Grade Corporate Active ETF (ARCA: IG)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, May 16, 2024
President Biden Posts On X "Too Many Lives Ha...
Benzinga Newsdesk
Wednesday, April 17, 2024
'Senator Presses Attorney General Garland On ...
Benzinga Newsdesk
Thursday, October 22, 2015
IGI Laboratories Sees FY15 Rev. $41-43M vs. E...
Benzinga
IGI Laboratories Reports Q3 EPS Breakeven vs....
Benzinga
IGI Laboratories To Rename Itself To Teligent...
Benzinga
Tuesday, October 13, 2015
IGI Laboratories, Inc. Enters Into Agreement ...
Benzinga
Monday, October 05, 2015
Morning Market Losers
Benzinga
IGI Laboratories, Inc. Announces Acquisition Of Three Commercialized Injectable Products, $10M Cash
Benzinga
IGI Laboratories Names Stephen Richardson Chi...
Benzinga
Thursday, August 20, 2015
The Coming Drug-Patent Cliff Is Pushing This Portfolio Up
Benzinga
Friday, July 24, 2015
Roth Capital: Time To Buy IGI Labs, 2016 Could Be 'Breakout Year'
Benzinga
Roth Capital Upgrades IGI Laboratories to Buy, Raises PT to $11.00
Benzinga
Thursday, July 23, 2015
IGI Labs Reports Q2 Loss $0.03 vs Loss $0.08,...
Benzinga
Thursday, July 09, 2015
IGI Laboratories, Inc. Announces FDA Approval And Commercial Launch Of Diclofenac Sodium, 1.5%
Benzinga
Tuesday, June 09, 2015
IGI Laboratories, Inc. Announces Fourth ANDA Submission of 2015
Benzinga
Wednesday, May 27, 2015
IGI Labs Expecting Q2 Gross Margin in 34-35% ...
Benzinga
Friday, May 01, 2015
IGI Laboratories Director Gale Buys 30,000 Sh...
Benzinga
Wednesday, April 29, 2015
Earlier: Avondale Partners Downgraded IGI Laboratories to Market Perform
Benzinga
Oppenheimer Downgrades IGI Laboratories to Perform
Benzinga
Morning Market Losers
Benzinga
Tuesday, April 28, 2015
IGI Labs Reports Q1 EPS $0.00 vs Est $0.01, S...
Benzinga
Tuesday, April 07, 2015
Deutsche Bank Initiates Coverage on IGI Laboratories at Buy, Announces $10.00 PT
Benzinga
Thursday, March 26, 2015
IGI Laboratories, Inc. Announces First ANDA Submission Of 2015
Benzinga
Monday, March 02, 2015
IGI Labs Reports Q4 EPS $0.09 Vs Est $0.06, S...
Benzinga
Tuesday, December 23, 2014
IGI Laboratories Submits Three Additional AND...
Benzinga
Wednesday, December 10, 2014
Morning Market Losers
Benzinga
Tuesday, December 09, 2014
IGI Laboratories Announces Proposed Offering ...
Benzinga
Monday, December 01, 2014
IGI Labs Reports 8th ANDA Submission of '14, ...
Benzinga
Friday, November 07, 2014
Credit Suisse Maintains Outperform on IGI Laboratories, Inc., Raises PT to $95.00
Benzinga
Thursday, October 23, 2014
IGI Laboratories, Inc. Reports Q3 EPS of $(0.01), Inline
Benzinga
Wednesday, October 01, 2014
IGI Laboratories Acquires 2 Products From Val...
Benzinga
IGI Labs Reports Purchase of Two Products fro...
Benzinga
Thursday, September 25, 2014
8-K from IGI Labs Shows Co. Paid ~$500K for 1...
Benzinga
Friday, June 27, 2014
IGI Labs Prices 4.65M Share Offering at $5/Sh...
Benzinga
Thursday, June 26, 2014
IGI Labs: Mallinckrodt Grants Non-Exclusive L...
Benzinga
IGI Labs. Announces Joint Stipulation
Benzinga
Friday, June 20, 2014
IGI Labs Completes ANDA Filing for 2014
Benzinga
Thursday, June 05, 2014
Form S-3 from IGI Labs Shows Registration for...
Benzinga
Monday, June 02, 2014
IGI Laboratories Announces Fifteens ANDA Subm...
Benzinga
Tuesday, April 29, 2014
IGI Laboratories, Inc. Reports Q1 EPS of $0.00 vs $0.01 Est; Revenue of $6.85M vs $6.02M Est
Benzinga
Monday, April 21, 2014
Craig-Hallum Initiates Coverage on IGI Laboratories, Inc. at Buy, Announces $7.50 PT
Benzinga
Wednesday, March 12, 2014
Shares of IG Labs Resume, Now Up 1.5%
Benzinga
UPDATE: IGI Labs Announces First ANDA Approval for Lidocaine Hydrochloride USP 4% Topical
Benzinga
IGI Laboratories Says FDA Approves Applicatio...
Benzinga
IGI Labs Halted News Pending
Benzinga
Wednesday, March 05, 2014
After-Hours Movers Mar. 5, 2014: ERII, PXLW, BIOD, SEED Higher, DVAX, LYV Lower
Benzinga
Thursday, February 27, 2014
IGI Laboratories, Inc. Reports Q4 EPS of $0.01, Inline; Revenue of $6.73M vs $5.60M Est
Benzinga
Tuesday, December 31, 2013
IGI Laboratories Completes Sixth ANDA Filing for 2013 Under Joint Drug Development And Commercialization Agreement
Benzinga
Tuesday, October 29, 2013
IGI Laboratories, Inc. Reports Q3 EPS of $0.00; Revenue of $4.0M
Benzinga
Wednesday, August 07, 2013
Roth Capital Initiates Coverage on IGI Laboratories, Inc. at Buy, Announces $3.50 PT
Benzinga
Show More